Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy 

June 10, 2026 12:03 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the closing of Teva’s acquisition of Emalex Biosciences, strengthening its late-stage pipeline with ecopipam and further advancing its Pivot to Growth strategy. Phase 3 data for ecopipam were recently published in JAMA Neurology, and a U.S. NDA submission is anticipated in the second half of 2026.  “This acquisition reflects our Pivot to […]

Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL

New Clinical Data, Patient Reported Outcomes, Real-World Utilization, and Comparative-Effectiveness Models to be Featured in Four Oral and One Poster Presentation June 10, 2026 08:00 ET  | Source: Kyowa Kirin PRINCETON, N.J., June 10, 2026 (GLOBE NEWSWIRE) — Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced new data further

Fertility Institute of Hawaii Joins Nucleus IVF+ Network as Demand for Genetic Optimization Continues to Expand

The partnership brings Nucleus’ advanced carrier and embryo screening to Hawaii’s largest IVF practice June 09, 2026 09:00 ET  | Source: Nucleus Genomics Inc. NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) — Nucleus Genomics today announced an IVF+ partnership with the Fertility Institute of Hawaii, bringing its advanced carrier screening and embryo analysis to Hawaii’s largest IVF practice. Through the collaboration, patients

Philips Future Health Index 2026: AI is already saving clinicians time and delivering measurable impact in healthcare

June 09, 2026 04:00 ET  | Source: Royal Philips June 9, 2026 Amsterdam, the Netherlands – AI is already saving clinicians the equivalent of over 16 working days a year and helping them see more patients, but healthcare systems risk falling behind because of inadequate training and fragmented infrastructure. That’s according to findings from Philips’ Future Health Index

Smith+Nephew announces first clinical cases with the next generation CORI◊XT Handheld Robotics Platform across knee and shoulder arthroplasty

June 08, 2026 13:23 ET  | Source: Smith & Nephew UK Ltd Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, announces the completion of the first clinical cases performed using the next‑generation CORI◊ XT Handheld Robotics Platform, marking an important milestone in the clinical introduction of its latest handheld robotics technology. CORI XT Handheld Robotic Platform is designed

Vantive Highlights Late-Breaking High Clinical Impact Data at ERA Indicating HDx Therapy is a Practical Alternative to Online Hemodiafiltration

June 08, 2026 13:15 ET  | Source: Vantive GLASGOW, Scotland, June 08, 2026 (GLOBE NEWSWIRE) — Vantive, a vital organ therapy company with a 70-year legacy of kidney care innovation, reports two late-breaking clinical studies indicating HDx therapy (expanded hemodialysis) enabled by the Theranova dialyzer provides similar (statistically non-inferior) all-cause mortality and major cardiovascular outcomes* compared with online hemodiafiltration (OL-HDF).1,2 The randomized

Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care

June 08, 2026 08:00 ET  | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J. and TEL AVIV, Israel, June 08, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data that highlight the comprehensive tardive dyskinesia (TD) symptom improvement from treatment with AUSTEDO® and AUSTEDO XR®. The

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity

June 07, 2026 14:30 ET  | Source: Boehringer Ingelheim Limited Ingelheim, Germany – Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without

EnGeneIC Honored with 2026 Breakthrough in Glioblastoma Biotech Award at Northwell Foundation Lenox Hill Neurosurgery Brain Cancer Gala in New York

June 05, 2026 11:48 ET  | Source: EnGeneIC SYDNEY and NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) — EnGeneIC Limited today announced it has been recognized with the Breakthrough in glioblastoma Biotech Award 2026 at the Northwell Foundation, Lenox Hill Neurosurgery Brain Tumor Center Gala event in New York City. The award was presented to Joint-CEO’s and

Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington’s Disease Chorea

June 05, 2026 11:30 ET  | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J. and TEL AVIV, Israel, June 05, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from the first and only real-world, decentralized study evaluating the patient- and caregiver-reported quality of life

New Health Economic Evidence Shows Health & Cost Benefits When Starting Dialysis at Home

June 05, 2026 04:30 ET  | Source: Vantive New UK economic analyses show improved patient outcomes and health system savings – including nearly £200 million in projected UK NHS savings over 5 years – through increased uptake of home-based peritoneal dialysis compared to in-center hemodialysis Findings highlight the importance of coordinated, patient-centric kidney care, including early referral,

Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®

June 04, 2026 08:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of AHZANTIVE (aflibercept), a biosimilar to Eylea®, in Europe further strengthening the Company’s growing biosimilars portfolio and expanding its presence in ophthalmology. The launch reflects Teva’s strategy to build a leading biosimilars business in

WellSpan Health and Philips Announce Landmark Strategic Alliance, Accelerating Innovation and Research Across Central Pennsylvania and Northern Maryland

June 04, 2026 04:00 ET  | Source: Royal Philips June 4, 2026 Seven-year collaboration puts WellSpan at the forefront of diagnostics and imaging in community health through a groundbreaking research and innovation strategy aimed at shaping the future of care delivery Amsterdam and YORK, Pa. – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology,

Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

June 03, 2026 16:05 ET  | Source: Iovance Biotherapeutics, Inc. First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering

Dark Horse Consulting Group and Altruist Biologics Announce Memorandum of Understanding to Advance Biologics Manufacturing and Development in China

June 03, 2026 07:00 ET  | Source: Dark Horse Consulting Group WALNUT CREEK, Calif. and SUZHOU, China, June 03, 2026 (GLOBE NEWSWIRE) — Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and Altruist Biologics, a wholly-owned subsidiary of Innovent Biologics and global contract development and manufacturing organization (CDMO) specializing

Scroll to Top